Recombinant Antithrombin Alleviated Pulmonary Injury and Inflammation in LPS-Induced ARDS by Inhibiting IL17a/NF-κB Signaling.
ImmunoTargets and therapy
Yang C, Fu C, Wang M, Zheng J, Gao Y, Zhu H, Li H, Li D, Guo L, Yu B, Dai Q.
Publication Overview
Key findings, Countstar context, and access to the original paper.
2025
Bioprocessing
Immunology
No items found.
Key Finding
The findings of this study suggest that rAT alleviates lung injury and suppresses inflammatory responses by inhibiting the IL17a/NF-κB signaling axis, suggesting that rAT may serve as a potential therapeutic agent for mitigating pulmonary inflammation and improving the prognosis of ARDS induced by sepsis.
Countstar Connection
The study obtained cell-count measurements from the study's cell samples with Countstar (model not specified) during quality assessment in the 2025 ImmunoTargets and therapy study.
